ALERA GROUP, INC. – Trademark Portfolio
Entity Type: 03
ALERA GROUP, INC. holds 44 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 36 (Insurance & Financial) — 25 filings in this category. The portfolio also extends into Class 35 (Advertising & Business) across 3 Nice Classification classes. Currently, 24 trademarks are registered and 12 are pending. Notable registered marks include A, BLUE, ALERA, ENROLLCA, and HEALTHSURE. The owner is based in DEERFIELD, IL.
THREE PARKWAY NORTH, SUITE 500
DEERFIELD, IL 60015
Showing of trademarks Trademarks
Trademark Classifications
ALERA GROUP, INC.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Insurance; financial affairs; monetary affairs; real estate affairs
Advertising; business management; business administration; office functions
Education; providing of training; entertainment; sporting and cultural activities
Frequently Asked Questions
How many trademarks does ALERA GROUP, INC. have?
ALERA GROUP, INC. has 44 U.S. trademarks filed with the USPTO. Of these, 24 registered, 12 pending, 5 abandoned, 3 cancelled.
What trademark classes does ALERA GROUP, INC. file in?
ALERA GROUP, INC. files trademarks across 3 Nice Classification classes. The most active classes are Class 36 (Insurance & Financial), Class 35 (Advertising & Business), Class 41 (Education & Entertainment). Class 36 covers insurance; financial affairs; monetary affairs; real estate affairs.
What are ALERA GROUP, INC.'s most well-known trademarks?
ALERA GROUP, INC.'s registered trademark portfolio includes well-known marks such as A, BLUE, ALERA, ENROLLCA, and HEALTHSURE. These are among 24 currently registered trademarks in the portfolio.
What is ALERA GROUP, INC.'s trademark registration success rate?
ALERA GROUP, INC. has a 75% trademark registration rate, with 24 out of 32 resolved applications resulting in successful registration. Currently, 12 applications are pending review.